[
  {
    "ts": null,
    "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
    "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
    "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757533740,
      "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
      "id": 136688576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
      "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery",
    "summary": "On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy). Inlexzo, previously referred to as TAR-200, is indicated for adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle",
    "url": "https://finnhub.io/api/news?id=ee984ac60441273d969303c6092d69723f2f9335248ccf0a667b95d9ab7d41a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757533269,
      "headline": "Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery",
      "id": 136688658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy). Inlexzo, previously referred to as TAR-200, is indicated for adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle",
      "url": "https://finnhub.io/api/news?id=ee984ac60441273d969303c6092d69723f2f9335248ccf0a667b95d9ab7d41a7"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
    "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
    "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520480,
      "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
      "id": 136688580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
      "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e"
    }
  },
  {
    "ts": null,
    "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
    "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
    "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520120,
      "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
      "id": 136688660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
      "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries",
    "summary": "Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.",
    "url": "https://finnhub.io/api/news?id=3ee50f1e7cd2cebf16a92d61ad92765b3ac75dc25928827bd59d1cbee83b739a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757516700,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries",
      "id": 136688661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.",
      "url": "https://finnhub.io/api/news?id=3ee50f1e7cd2cebf16a92d61ad92765b3ac75dc25928827bd59d1cbee83b739a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
    "summary": "Get key insights from Johnson & Johnsonâs 2025 healthcare",
    "url": "https://finnhub.io/api/news?id=6c6f3b86abb42b098ca6d06f4c905c64a2a5f136e7ecfd86a30f43a9c64e6be9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757516127,
      "headline": "Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
      "id": 136685920,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Get key insights from Johnson & Johnsonâs 2025 healthcare",
      "url": "https://finnhub.io/api/news?id=6c6f3b86abb42b098ca6d06f4c905c64a2a5f136e7ecfd86a30f43a9c64e6be9"
    }
  },
  {
    "ts": null,
    "headline": "Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG?",
    "summary": "Intuitive Surgical's Ion platform is driving rapid growth, but cost optimization could be the key to turning it from a margin drag to a margin lever.",
    "url": "https://finnhub.io/api/news?id=96a6e30c5714725e2c6c7744d9c9932abff2b5616872ffb20be1f82cf8361841",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757512560,
      "headline": "Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG?",
      "id": 136688662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Intuitive Surgical's Ion platform is driving rapid growth, but cost optimization could be the key to turning it from a margin drag to a margin lever.",
      "url": "https://finnhub.io/api/news?id=96a6e30c5714725e2c6c7744d9c9932abff2b5616872ffb20be1f82cf8361841"
    }
  },
  {
    "ts": null,
    "headline": "MedtechWOMEN Announces Virginia L. Giddings as Winner of the 2025 Ferolyn Powell Award",
    "summary": "MENLO PARK, Calif., September 10, 2025--MedtechWOMEN today announced that Virginia Giddings, Ph.D., vice president of Exploration at Edwards Lifesciences, has been named the recipient of the 2025 Ferolyn Powell Leadership Award, honoring her extraordinary contributions to advancing healthcare innovation, mentoring the next generation of leaders, and fostering diversity in the medical technology industry.",
    "url": "https://finnhub.io/api/news?id=e66a99716dd6e0b26bfcca02052898a50ba03da88e20c9455193508b8dbe7be0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757509200,
      "headline": "MedtechWOMEN Announces Virginia L. Giddings as Winner of the 2025 Ferolyn Powell Award",
      "id": 136688663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MENLO PARK, Calif., September 10, 2025--MedtechWOMEN today announced that Virginia Giddings, Ph.D., vice president of Exploration at Edwards Lifesciences, has been named the recipient of the 2025 Ferolyn Powell Leadership Award, honoring her extraordinary contributions to advancing healthcare innovation, mentoring the next generation of leaders, and fostering diversity in the medical technology industry.",
      "url": "https://finnhub.io/api/news?id=e66a99716dd6e0b26bfcca02052898a50ba03da88e20c9455193508b8dbe7be0"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate $1 Million All-Weather Portfolio For Lifetime Wealth",
    "summary": "Monte Carlo simulations revealed how sector diversification and correlations impact long-term portfolio resilience. Click here for more information on Retirement.",
    "url": "https://finnhub.io/api/news?id=78abd7dfdd47ac6881ddc11a377a45e5ec9beca217d324733c8c856fe9034eb8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757501926,
      "headline": "The Ultimate $1 Million All-Weather Portfolio For Lifetime Wealth",
      "id": 136684790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401505902/image_1401505902.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Monte Carlo simulations revealed how sector diversification and correlations impact long-term portfolio resilience. Click here for more information on Retirement.",
      "url": "https://finnhub.io/api/news?id=78abd7dfdd47ac6881ddc11a377a45e5ec9beca217d324733c8c856fe9034eb8"
    }
  },
  {
    "ts": null,
    "headline": "J&J obtains FDA approval for gemcitabine intravesical system",
    "summary": "Inlexzo is said to be the first intravesical drug releasing system that enables prolonged local delivery of a cancer treatment directly into the bladder.",
    "url": "https://finnhub.io/api/news?id=de2deaa333366ed92f648305e9d59cc6b485e1ce1bbf9e630cbb9057b08b3a7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757499215,
      "headline": "J&J obtains FDA approval for gemcitabine intravesical system",
      "id": 136688664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Inlexzo is said to be the first intravesical drug releasing system that enables prolonged local delivery of a cancer treatment directly into the bladder.",
      "url": "https://finnhub.io/api/news?id=de2deaa333366ed92f648305e9d59cc6b485e1ce1bbf9e630cbb9057b08b3a7f"
    }
  },
  {
    "ts": null,
    "headline": "Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.",
    "summary": "While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.",
    "url": "https://finnhub.io/api/news?id=b28040e0dd55cb8a50885830067c1799b807e6849ab6514102edae769db1bb7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757494800,
      "headline": "Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.",
      "id": 136688665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.",
      "url": "https://finnhub.io/api/news?id=b28040e0dd55cb8a50885830067c1799b807e6849ab6514102edae769db1bb7a"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “Their Core Pharma Business is Roaring”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer picked for his fantasy stock portfolio. Cramer made some positive comments about the company, as he commented: “JNJ’s up roughly 23% year to date. I couldn’t believe it, I saw it was like 180. It was amazing. Weak action throughout most of the healthcare, […]",
    "url": "https://finnhub.io/api/news?id=844166d04877c5c50b05a544eebe85b1636202578f8726192ca9e2ba0f72f699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757481040,
      "headline": "Jim Cramer on Johnson & Johnson: “Their Core Pharma Business is Roaring”",
      "id": 136688666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer picked for his fantasy stock portfolio. Cramer made some positive comments about the company, as he commented: “JNJ’s up roughly 23% year to date. I couldn’t believe it, I saw it was like 180. It was amazing. Weak action throughout most of the healthcare, […]",
      "url": "https://finnhub.io/api/news?id=844166d04877c5c50b05a544eebe85b1636202578f8726192ca9e2ba0f72f699"
    }
  }
]